Ardelyx (NASDAQ:ARDX) Sets New 52-Week Low – Time to Sell?

Posted by Brian Himes on Sep 2nd, 2026

Ardelyx, Inc. (NASDAQ:ARDX – Get Free Report) hit a new 52-week low on Monday . The stock traded as low as $3.71 and last traded at $3.7150, with a volume of 312528 shares traded. The stock had previously closed at $3.81.

Analyst Ratings Changes

Several equities analysts have recently commented on ARDX shares. Zacks Research lowered shares of Ardelyx from a “hold” rating to a “strong sell” rating in a research report on Wednesday, July 22nd. HC Wainwright reiterated a “buy” rating and issued a $13.00 price objective on shares of Ardelyx in a research report on Friday, August 7th. Wedbush reissued an “outperform” rating and set a $9.00 target price on shares of Ardelyx in a research note on Tuesday, August 18th. TD Cowen decreased their target price on shares of Ardelyx from $13.00 to $10.00 and set a “buy” rating for the company in a research report on Friday, August 7th. Finally, BTIG Research dropped their price target on shares of Ardelyx from $17.00 to $14.00 and set a “buy” rating on the stock in a research note on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat, Ardelyx presently has an average rating of “Moderate Buy” and an average target price of $13.90.

Check Out Our Latest Report on Ardelyx

Ardelyx Stock Performance

The firm’s 50-day simple moving average is $4.74 and its two-hundred day simple moving average is $5.62. The company has a current ratio of 3.34, a quick ratio of 3.15 and a debt-to-equity ratio of 1.69. The stock has a market capitalization of $936.95 million, a PE ratio of -17.09 and a beta of 0.70.

Ardelyx (NASDAQ:ARDX – Get Free Report) last issued its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02). Ardelyx had a negative net margin of 12.35% and a negative return on equity of 36.00%. The business had revenue of $120.88 million during the quarter, compared to analyst estimates of $121.03 million. During the same quarter in the prior year, the company earned ($0.08) EPS. Ardelyx’s revenue for the quarter was up 34.3% on a year-over-year basis. On average, equities research analysts expect that Ardelyx, Inc. will post -0.2 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, insider Mike Kelliher sold 7,758 shares of the firm’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $3.86, for a total value of $29,945.88. Following the sale, the insider directly owned 349,660 shares of the company’s stock, valued at approximately $1,349,687.60. This trade represents a 2.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Michael Raab sold 58,574 shares of the stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $3.86, for a total value of $226,095.64. Following the sale, the chief executive officer owned 1,619,792 shares of the company’s stock, valued at approximately $6,252,397.12. The trade was a 3.49% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 126,059 shares of company stock valued at $486,588. 5.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Ardelyx

Several hedge funds and other institutional investors have recently modified their holdings of ARDX. Northwestern Mutual Wealth Management Co. bought a new position in Ardelyx during the second quarter worth $35,000. SCS Capital Management LLC bought a new stake in Ardelyx in the 2nd quarter valued at $52,000. ADAR1 Capital Management LLC acquired a new stake in Ardelyx in the 2nd quarter worth $56,000. State of Wyoming acquired a new stake in Ardelyx in the 2nd quarter worth $61,000. Finally, PVG Asset Management Corp bought a new position in shares of Ardelyx during the 1st quarter worth about $65,000. Institutional investors and hedge funds own 58.92% of the company’s stock.

Ardelyx Company Profile

(Get Free Report)

Ardelyx, Inc (NASDAQ: ARDX) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing targeted small molecule drugs for cardio‐renal and gastrointestinal diseases. The company’s lead marketed product, tenapanor (sold under the brand name XPHOZAH in the United States), is approved for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. Ardelyx’s proprietary approach targets epithelial transporters in the gastrointestinal tract, offering localized activity with limited systemic exposure.

Beyond tenapanor, Ardelyx’s development pipeline includes treatments designed to address other complications in kidney disease and related metabolic disorders.